Rituximab in refractory Vogt–Koyanagi–Harada disease
NAGIOS: RODERIC FUNCIONANDO

Rituximab in refractory Vogt–Koyanagi–Harada disease

DSpace Repository

Rituximab in refractory Vogt–Koyanagi–Harada disease

Show simple item record

dc.contributor.author Dolz-Marco, Rosa es_ES
dc.contributor.author Gallego Pinazo, Roberto es_ES
dc.contributor.author Díaz Llopis, Manuel es_ES
dc.date.accessioned 2015-06-22T09:51:17Z
dc.date.available 2015-06-22T09:51:17Z
dc.date.issued 2011 es_ES
dc.identifier.uri http://hdl.handle.net/10550/44675
dc.description.abstract IntroductionVogt–Koyanagi–Harada (VKH) prognosis depends on early recognition and treatment; chronic disease may be developed when either delayed or inadequate treatment is performed, whereas other cases despite correct treatment are refractory to different drugs and also become chronic. We report a case of refractory VKH controlled with rituximab treatment.Case reportA 41-year-old female with painful visual loss and headache was examined. (VA 0.4 in RE and hand movements (HM) in LE). Retinal examination demonstrated multiple serous retinal detachments in both eyes. High-dose oral steroids were started, followed by progressive tapering of prednisone. New acute anterior and posterior relapses were achieved, and other immunommodulators were progressively added—new high-dose steroid treatment, adalimumab, cyclosporine, and methotrexate—but patient had new anterior and posterior recurrences associated with tinnitus and headache. Thus, an infusion of 1 g of rituximab was administered after 15 months follow-up; the VA was 0.2 in RE and counting fingers in LE. Three additional doses of 1 g each were administered 1, 6, and 16 months later. We have achieved a final VA after 34 months follow-up of 0.2 in RE and HM in LE, with definitive control of inflammation, without acute relapses since rituximab was administered.ConclusionAfter searching PubMed/Medline, this is the first report of VKH disease treated with rituximab. Additional studies are warranted to confirm the efficacy of this new approach for inflammatory control in refractory cases of VKH disease. es_ES
dc.source Journal of Ophthalmic Inflammation and Infection Vol. 1 Issue 4: pp. 177-180 es_ES
dc.subject Chronic VKH es_ES
dc.subject Rituximab es_ES
dc.subject Immunommodulators es_ES
dc.title Rituximab in refractory Vogt–Koyanagi–Harada disease es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.identifier.doi 10.1007/s12348-011-0027-9 es_ES
dc.identifier.idgrec 075349 es_ES

View       (524.7Kb)

This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search

Browse

Statistics